DailyIQ
Last updatedjust now

CVS·CVS Health Corporation

$90.43
+2.88 (+3.29%)
After Hours
High
$90.78
Open
$88.10
Market Cap
112.33B
52W High
$111.66
Low
$87.50
P. Close
$90.43
P/E
22.97
52W Low
$69.51
Fwd P/E
10.26
DailyIQ Est.
$119.92
Inst. Ownership
48.1%
Short Interest
1.29%
Days to Cover
1.7
Div. Yield
3.03%
Next Ex-Div
~Oct 22
Technical Score (1D)
50
NEUTRAL
News Sentiment
31
BEARISH
On Oct 13, CVS Pharmacy Inc. agreed to pay $315 million to settle a Justice Department lawsuit alleging illegal dispensing of controlled substances and fraudulent billing over 12 years. The settlement was reached after the DOJ accused CVS of unlawfully fulfilling opioid prescriptions and billing federal programs for them. CVS denied any wrongdoing in the lawsuit, but the payment represents a material cost to the company and adds to regulatory pressure. The agreement also includes compliance measures such as a hotline and dispensing monitoring, and it resolves a whistleblower lawsuit without confirming liability. The settlement removes a significant regulatory headwind tied to CVS’s historical dispensing practices, potentially reducing future compliance scrutiny. The news was reported as a material negative event for the firm, though it contributed to a modest rise in CVS shares.
LOW TARGET
$103 +13.9%
2 analysts
MEAN TARGET
$115 +27.8%
9 analysts
HIGH TARGET
$145 +60.4%
24 analysts
PRICE RANGE
$103.00 - $145.00
SB / B / H / S / SS
8/20/5/1/1
DAILYIQ EST.
$119.92 (+32.7%)
Sector
Healthcare
Industry
Healthcare Plans
Exchange
NYQ
Country
United States
Symbol
CVS
Description
CVS Health Corporation is a diversified healthcare company operating primarily within the United States, offering a comprehensive suite of health solutions. The company's core business is segmented into Healthcare Benefits, Health Services, and Pharmacy & Consumer Wellness. Through its Healthcare Benefits arm, CVS provides a range of health insurance products and services, catering to a diverse clientele including employers, individuals, and government entities. The Health Services segment focuses on pharmacy benefit management, offering solutions for plan design, formulary management, and other administrative functions. Finally, the Pharmacy & Consumer Wellness segment encompasses retail pharmacy operations, selling prescription drugs, over-the-counter medications, and health-related consumer products, along with related services.
Bought (1Y)
0 shares
$0
Sold (1Y)
3,760,550 shares
$353.7M
Clark James DavidSVP, Cont & Chief Acct Officer
Tax Withholding454 shares2026-06-26
Compton-Phillips AmyEVP, Chief Medical Officer
Tax Withholding7,618 shares2026-05-31
Newman BrianEVP, Chief Financial Officer
Tax Withholding2,478 shares2026-05-31
AGUIRRE FERNANDO-
D1,563 shares2026-05-21
ROBBINS LARRY-
Sell378,000 shares2026-05-21
66/ 100
Bullish
Overall: Bullish
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Gross Margin
45.0%
Net Margin
0.4%
Revenue CAGR
9.7%
Current Ratio
0.84x
Debt / Equity
0.80x
Return on Equity
2.4%
Earnings Summary
CVS Health Corporation operates as a diversified U.S. healthcare provider with three main segments: Healthcare Benefits, Health Services, and Pharmacy & Consumer Wellness, positioning it within the broader healthcare plans sector. The company’s business model blends insurance, pharmacy benefit management, and retail pharmacy operations, giving it multiple revenue streams. In the most recent quarters, CVS delivered strong earnings momentum: Q4 2024 EPS of $1.19 beat the $0.92 estimate, while Q1 2025 EPS rose to $2.25 versus a $1.67 estimate, and Q2 2025 EPS of $1.81 outpaced the $1.46 forecast. Revenue also trended upward, with Q2 2025 sales of $98.9 billion and Q3 2025 $102.9 billion, reflecting a steady 4–5% growth over the prior year’s comparable periods. The company has consistently surpassed analyst expectations in the last four quarters, with EPS beats in each period and revenue growth maintained even when EPS growth slowed slightly in Q4 2025. Historically, CVS has shown a YoY revenue expansion of roughly 3–4% annually, while EPS growth has accelerated from $1.19 in Q4 2024 to $2.57 in Q1 2026, underscoring a robust earnings trajectory. Recent news highlights the launch of nearly 20 new neighborhood pharmacy sites in 2026 and the opening of a flagship CVS Pharmacy in Boston, initiatives aimed at boosting foot traffic and prescription sales. The company also faced Medicare Advantage star rating setbacks, which could reduce quality bonus payments and impact future earnings.

EPS

EstBeatMiss
$0.77$1.28$1.79$2.30$2.82Q2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$1.65 - -
Q2'26$1.87$2.58+38.0%
Q1'26$2.21$2.57+16.5%
Q4'25$1.00$1.09+8.8%
Q3'25$1.36$1.60+17.9%
Q2'25$1.46$1.81+23.9%

Revenue

EstBeatMiss
$93.4B$97.0B$100.6B$104.2B$107.8BQ2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$105.5B - -
Q2'26$101.1B$106.1B+4.9%
Q1'26$95.0B$100.4B+5.7%
Q4'25$104.6B$105.7B+1.0%
Q3'25 - $102.9B -
Q2'25 - $98.9B -

Market Data

CVS Stock Snapshot

NEUTRAL50/100
$90.39−$0.04 (0.0%)
Market cap
112.33B
P/E ratio
23.0
Day range
$87.50 – $90.78
News sentiment
31/100 · Bearish
Analyst target
$115.48 (+27.8%)
Consensus
Buy · 35 analysts
52-week range+30.0% off low · -19.0% from high
$69.51$111.66
Price $90.39 DailyIQ Est. $119.92

The technical read on CVS is balanced, which usually means the market is waiting on a catalyst. Institutional coverage is thorough here, so shifts in analyst expectations show up in price quickly.

Reverse DCF

What growth is priced into CVS?

CHEAP

At today's price, CVS Health Corporation needs to grow free cash flow about -1.8% a year for the next 10 years to justify its valuation at a 6.52% cost of capital. Over its actual history it has compounded free cash flow at 11.7% a year, so the market is asking for 13.5 percentage points below its own delivered rate. On that basis CVS looks priced below what its own growth record supports.

Implied FCF growth
-1.8%
Historical FCF CAGR
11.7%
Growth gap
-13.5 pts
Verdict
CHEAP
Discount rate (WACC)
6.52%
Beta
0.51

Behaviour On Record

What CVS's own history says about today's numbers

Realized volatility (21d)
27.9% 73rd pct
Below its peak
-22.8%
vs 200-day average
-0.4%
Up days (1y)
49%

CVS Health Corporation is currently running 27.9% annualised volatility over the last 21 sessions. Measured against CVS's own 13 years of daily returns rather than a market-wide average, that is the 73rd percentile — a little above its own norm, against a typical reading of 22.8%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

CVS is trading -22.8% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -23.8%, and the deepest was -46.7% in 2024. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.

Price sits -0.4% from its 200-day moving average. Against every other day in its history, that gap ranks at the 49th percentile — close to the gap it normally carries. Over the past year CVS closed higher on 49% of sessions, and it is currently 1 session into a falling streak.

On October specifically: over 13 years of records, CVS finished the month higher 6 of 13 times, with a median return of -0.7% and an average of -0.9%. Its strongest month historically has been November at +4.6% on average, its weakest March at -1.3%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: CVS has opened more than 2% away from the prior close in 41 of 3,265 sessions (1.3% of the time), with the largest gaps running +5.1% and -7.4%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 3 dated reports on file, CVS moved an average of 1.6% in the session after earnings, closing higher 2 of those 3 times, with a median move of +0.3% and a largest of -3.0%.

All figures computed from 3,266 daily closes between 2013-10-15 and 2026-10-13, split-adjusted, recomputed daily. Percentiles are against CVS's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of CVS's sector?

CVS Health Corporation sits in the Health Care sector, currently ranked 2nd of 12 GICS sectors by relative-strength rotation score (leading).

Sector rank
#2 of 12
Sector state
Leading
Sector rotation score
82

Options Market

What is the options market pricing for CVS?

CallsPuts

For CVS Health Corporation's nearest expiry (2026-10-16, 2 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.72), with at-the-money implied volatility around 38.0%. The options market is pricing roughly a ±2.6% move by that expiry — a range of about $85.27–$89.83.

Put/call ratio (2026-10-16)
0.72
ATM implied volatility
38.0%
Total open interest
35,922
Expected move by 2026-10-16
±2.6% ($85.27–$89.83)

Analyst Rating Changes

Are analysts turning bullish or bearish on CVS?

Leerink Partners most recently reiterated its rating on CVS Health Corporation to Outperform on Oct 12, 2026 with a price target of $112 (from $119). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.

Latest action
Leerink Partners — Outperform
90-day upgrades
0
90-day downgrades
0
Net rating momentum
0
DateFirmActionRatingPrice target
Oct 12, 2026Leerink PartnersMaintainedOutperform$119 → $112
Sep 3, 2026UBSMaintainedBuy$126 → $118
Aug 19, 2026Argus ResearchMaintainedBuy$104 → $114
Aug 12, 2026JP MorganMaintainedOverweight$111 → $118
Aug 6, 2026UBSMaintainedBuy$122 → $126
Aug 6, 2026Evercore ISI GroupMaintainedOutperform$130 → $125
Aug 6, 2026BarclaysMaintainedOverweight$106 → $108
Jul 25, 2026UBSMaintainedBuy$115 → $122
Jul 14, 2026Truist SecuritiesMaintainedBuy$108 → $118
Jul 13, 2026Wells FargoMaintainedOverweight$103 → $123
Jul 9, 2026RBC CapitalMaintainedOutperform$107 → $113
Jul 7, 2026Cantor FitzgeraldMaintainedOverweight$100 → $110

Peers & ETF holders

CVS peers & ETF holders

News Sentiment Analysis

Sentiment gathered from recent headlines

31/100
Strong NegativeNeutralStrong Positive
BEARISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
On October 13, CVS Pharmacy agreed to pay $315 million to resolve a Department of Justice opioid lawsuit, while denying any wrongdoing. The settlement follows accusations that CVS pharmacies were understaffed and improperly dispensed controlled substances. CVS stated it would implement additional safeguards to ensure opioid prescriptions are medically appropriate. The payment represents a significant financial outlay but is not expected to materially impact the company’s overall financial performance.
What did this article say?
CVS Health agreed to pay $315 million to resolve allegations that it illegally filled prescriptions for opioids and other controlled substances and billed Medicare and other federal healthcare programs for them. The settlement was announced by the Justice Department and confirmed CVS’s involvement in the alleged misconduct. The payment represents a significant financial hit and regulatory penalty for the company. The news contributed to a modest rise in CVS shares, but the overall impact is viewed as a material negative event for the firm.
What did this article say?
CVS Pharmacy Inc. agreed to pay $315 million to settle a federal lawsuit alleging the chain illegally dispensed controlled substances and fraudulently billed federal programs over a 12‑year period. The settlement resolves a major regulatory headwind tied to CVS’s historical dispensing practices and includes a memorandum of agreement with the DEA that imposes stringent institutional safeguards across its retail footprint. The DOJ’s allegations centered on systematic filling of invalid prescriptions, early refills, and high‑risk drug cocktails, driven by internal metrics, incentive structures, and understaffing. The settlement ends the lawsuit but imposes significant financial and operational costs on CVS.
What did this article say?
CVS Health and its affiliates agreed to pay $315 million to settle allegations that they illegally filled opioid prescriptions and billed federal programs for them. The settlement covers violations from October 2013 to December 2025 and involves compliance measures such as a hotline and dispensing monitoring. The agreement resolves a whistleblower lawsuit and does not confirm liability, but it imposes significant financial and operational costs on CVS.
What did this article say?
On October 13, CVS Health announced it would pay $315 million to settle federal claims that it knowingly filled illegal opioid prescriptions. The settlement follows accusations that the pharmacy chain filled controlled substances lacking legitimate medical purpose or valid prescriptions. The payment represents a significant financial hit and regulatory penalty for CVS, underscoring ongoing scrutiny of its prescription practices. The settlement may impact the company’s reputation and could prompt stricter oversight of its pharmacy operations.
What did this article say?
Aetna, a subsidiary of CVS Health, pledged $240,000 to the nonprofit GENYOUth to fund nutrition equipment and physical activity kits for 40 schools across six states. The donation aims to combat student hunger and promote healthy habits among children. The initiative covers schools in West Virginia, Florida, Missouri, Ohio, North Carolina, and Pennsylvania. While the contribution reflects CVS Health’s community engagement, it does not represent a material financial event for the company.
What did this article say?
On October 10, CVS Health announced plans to open nearly 20 new neighborhood pharmacy sites in 2026, including a location in Roxbury, Boston. The expansion signals a continued focus on the pharmacy‑centric business model, but the company faces headwinds from Medicare Advantage star rating setbacks and an ongoing legal probe. Meanwhile, CVS secured an extended distribution agreement with Cardinal Health and reaffirmed its dividend, providing some stability. The mixed outlook suggests a mild negative impact on the company’s short‑term valuation, though the long‑term growth prospects remain intact.
What did this article say?
In early October 2026, CVS Health launched its first pharmacy‑focused CVS Pharmacy in Boston and announced plans to open nearly 20 smaller neighborhood pharmacies across the United States during 2026. The company also continued to reshape its retail footprint by adding store‑in‑store locations and expanding clinic services. Concurrently, CVS’s Aetna unit faced updated Medicare Advantage star ratings that influence quality bonus eligibility, adding a new dimension to its revenue mix. These moves signal a strategic shift toward higher‑traffic, community‑based retail formats and a tighter integration of health‑care services, potentially boosting foot traffic and prescription sales.
What did this article say?
During the October 6 episode of Mad Money, Jim Cramer reviewed CVS Health’s recent performance, noting that the company’s second‑quarter revenue rose 7.3% to $106.1 billion and adjusted earnings per share climbed to $2.58 from $1.81. The insurer’s medical benefit ratio improved, and CVS raised its full‑year adjusted EPS guidance to $7.90‑$8.10. Cramer highlighted that, despite the stock’s sharp retreat from summer highs, the underlying turnaround appears to be continuing, suggesting a positive outlook for the company’s fundamentals.

Technical Analysis

Real-time indicators across multiple timeframes

50
NEUTRAL
Momentum rank against about 1,000 stocks and ETFs for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $59.68B combined position · 11 adding, 14 trimming, 0 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
BlackRock, Inc.▼ Sell123,223,4099.63%$12.75B2026-08-07
Vanguard Group Inc▲ Buy120,709,5309.43%$9.58B2026-01-29
Capital World Investors▼ Sell74,951,9555.86%$7.75B2026-08-12
Wellington Management Group LLP▲ Buy33,801,1132.64%$3.50B2026-08-14
Geode Capital Management, LLC▲ Buy29,899,6532.34%$3.08B2026-08-12
FMR LLC (Fidelity)▼ Sell28,920,6172.26%$2.99B2026-08-13
Capital Research Global Investors▲ Buy24,329,1511.90%$2.52B2026-08-12
Bank of America Corp▲ Buy23,188,6701.81%$2.40B2026-08-14
JPMorgan Chase & Co▼ Sell22,112,9701.73%$2.29B2026-08-12
Invesco Ltd.▼ Sell20,595,4311.61%$2.13B2026-08-14
Morgan Stanley▲ Buy18,606,0281.45%$1.92B2026-08-13
Norges Bank▼ Sell18,038,9221.41%$1.87B2026-08-12
Goldman Sachs Group Inc▲ Buy13,411,8071.05%$1.39B2026-08-14
Davis Selected Advisers▼ Sell11,865,9160.93%$1.23B2026-08-11
Northern Trust Corp▼ Sell11,471,8300.90%$1.19B2026-08-13
Glenview Capital Management, LLC▼ Sell4,824,7990.38%$499.13M2026-08-14
Citadel Advisors LLC▼ Sell4,812,5300.38%$497.86M2026-09-02
Wells Fargo & Company▼ Sell3,682,1780.29%$380.92M2026-08-14
Viking Global Investors LP▲ New3,663,3610.29%$378.97M2026-08-14
Janus Henderson Group plc▼ Sell3,536,8610.28%$254.02M2026-05-18
AQR Capital Management LLC▲ Buy2,411,9370.19%$248.94M2026-08-14
AllianceBernstein L.P.▲ Buy3,233,0000.25%$232.19M2026-08-14
Millennium Management LLC▲ Buy2,164,8330.17%$223.95M2026-08-14
Point72 Asset Management, L.P.▼ Sell1,961,0320.15%$202.87M2026-08-14
Citigroup Inc▼ Sell1,811,8570.14%$187.44M2026-08-03
Q2 2026 flow:37.59M sh bought ($3.87B)31.45M sh sold ($3.25B)net +6.14M sh (+$616.77M)
Congressional Trading Activity
25 disclosed trades · ~$316.0K est. traded value · 8 buys, 17 sells
MemberChamberStateTypeAmountTradedFiled
Alan ArmstrongSenateOK▲ Buy$1K - $15K2026-03-272026-07-21
John BoozmanSenateAR▲ Buy$1K - $15K2026-01-292026-02-15
Dwight EvansHousePA03▼ Sell$1K - $15K2025-11-212026-05-15
Lisa McClainHouseMI09▼ Sell$1K - $15K2025-10-312025-11-21
Lisa McClainHouseMI09▼ Sell$1K - $15K2025-10-302025-11-21
Lisa McClainHouseMI09▲ Buy$1K - $15K2025-10-302025-11-21
Adam SmithHouseWA09▼ Sell$1K - $15K2025-08-082025-08-08
Rob BresnahanHousePA08▼ Sell$1K - $15K2025-05-152025-05-31
Jefferson ShreveHouseIN06▼ Sell$15K - $50K2025-05-122025-06-22
Julie JohnsonHouseTX32▼ Sell$1K - $15K2025-04-012025-05-14
Rob BresnahanHousePA08▲ Buy$1K - $15K2025-02-252025-03-27
James French HillHouseAR02▼ Sell$15K - $50K2025-01-312025-02-04
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2025-01-242025-02-11
Julie JohnsonHouseTX32▼ Sell$1K - $15K2025-01-152025-02-12
Valerie HoyleHouseOR04▲ Buy$1K - $15K2024-10-292025-09-12
Tommy TubervilleSenateAL▼ Sell$1K - $15K2024-08-262026-08-05
Jerry MoranSenate-▼ Sell$1K - $15K2023-12-142024-01-17
Pete RickettsSenateNE▼ Sell$50K - $100K2023-09-212023-10-20
Dan SullivanSenateAK▼ Sell$1K - $15K2023-08-222023-09-22
Dan SullivanSenateAK▼ Sell$1K - $15K2023-01-102023-02-13
Jerry MoranSenate-▼ Sell$1K - $15K2021-12-212022-01-21
Bill CassidySenateLA▼ Sell$1K - $15K2020-11-052020-12-08
Jerry MoranSenate-▲ Buy$1K - $15K2020-08-212020-09-08
Jerry MoranSenate-▼ Sell$1K - $15K2019-09-252020-08-05
Sheldon WhitehouseSenateRI▲ Buy$1K - $15K2019-08-272019-10-08